임상 한눈에 보기

• 7건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 1건 · 완료/종료 5건
• Phase: Phase 2 · Phase 3 · Phase 1 · Phase 1, Phase 2
• Status: Recruiting · Completed · Withdrawn
• 주요 endpoint: Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. · Establishing predictive and prognostic indices based on qualification and exploratory markers to predict pCR and residual cancer burden (RCB). · To determine three- and five-year relapse-free survival (RFS) and OS among the treatment arms. · To determine incidence of adverse events (AEs) · serious adverse events (SAEs)
• 등록 대상자(표본 합산): 약 5,766명
• 선택한 코호트 보고값: ORR 27.8%
• 핵심: The purpose of this study is to demonstrate that SYD985 \[(vic-)trastuzumab duocarmazine\] is superior to physician's ch…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.